The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta

Journal of Orthopaedic Research

Volumn 26, Issue 2, 2008, Pages 153-164

  Delos, Demetris ^a   Yang, Xu ^a   Ricciardi, Benjamin F ^a   Myers, Elizabeth R ^a   Bostrom, Mathias P G ^a   Camacho, Nancy Pleshko ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Antiresorptives; Fracture healing; Mice; Osteogenesis imperfecta; RANKL; Receptor activator of nuclear factor B

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B IMMUNOGLOBULIN FC FRAGMENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE RADIOGRAPHY; BONE STRENGTH; CALLUS; CONTROLLED STUDY; DIAPHYSIS; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; FEMUR FRACTURE; FEMUR OSTEOTOMY; FRACTURE HEALING; MOUSE; NONHUMAN; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; TREATMENT OUTCOME; WILD TYPE; ANIMAL; BONE; DRUG ANTAGONISM; FEMALE; GENETICS; HOMOZYGOTE; IMAGE PROCESSING; MALE; MECHANICAL STRESS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; BIOMECHANICS; BONE AND BONES; DISEASE MODELS, ANIMAL; FEMALE; FRACTURE HEALING; HOMOZYGOTE; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE; MICE, TRANSGENIC; OSTEOGENESIS IMPERFECTA; RANK LIGAND; STRESS, MECHANICAL;

EID: 38849188820     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20469     Document Type: Article

References (59)

1. Rowe DW SJ. 1998. Osteogenesis imperfecta. In: Avioli LV, Krane SM, editors. Metabolic bone disease and clinically related disorders. San Diego, CA: Academic Press; p 651-683.
2. Rauch F, Glorieux FH. 2004. Osteogenesis imperfecta. Lancet 363:1377-1385.
3. Brumsen C, Hamdy NA, Papapoulos SE. 1997. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283.
4. Plotkin H, Rauch F, Bishop NJ, et al. 2000. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850.
5. Rauch F, Plotkin H, Zeitlin L, et al. 2003. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610-614.
6. Rauch F, Plotkin H, Travers R, et al. 2003. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986-992.
7. Rauch F, Travers R, Plotkin H, et al. 2002. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299.
8. Glorieux FH, Bishop NJ, Plotkin H, et al. 1998. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.
9. Zacharin M, Bateman J. 2002. Pamidronate treatment of osteogenesis imperfecta - lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 15:163-174.
10. Montpetit K, Plotkin H, Rauch F, et al. 2003. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 111(5 Pt 1):e601-e603.
11. Lee YS, Low SL, Lim LA, et al. 2001. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 160:641-644.
12. Banerjee I, Shortland GJ, Evans WD, et al. 2002. Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child 87:562-563.
13. Giraud F, Meunier PJ. 2002. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint Bone Spine 69:486-490.
14. Shapiro JR, McCarthy EF, Rossiter K, et al. 2003. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 72:103-112.
15. Adami S, Gatti D, Colapietro F, et al. 2003. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126-130.
16. Letocha AD, Cintas HL, Troendle JF, et al. 2005. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977-986.
17. Sakkers R, Kok D, Engelbert R, et al. 2004. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427-1431.
18. Gatti D, Antoniazzi F, Prizzi R, et al. 2005. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758-763.
19. Munns CF, Rauch F, Zeitlin L, et al. 2004. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779-1786.
20. Evans KD, Lau ST, Oberbauer AM, et al. 2003 Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone 32:268-274.
21. Khan SA, Kanis JA, Vasikaran S, et al. 1997. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700-1707.
22. Lacey DL, Timms E, Tan HL, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
23. Simonet WS, Lacey DL, Dunstan CR, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
24. Hofbauer LC, Schoppet M. 2004. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495.
25. Bekker PJ, Holloway D, Nakanishi A, et al. 2001. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360.
26. Body JJ, Greipp P, Coleman RE, et al. 2003. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (3 Suppl): 887-892.
27. Oyajobi BO, Anderson DM, Traianedes K, et al. 2001. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 61:2572-2578.
28. Zhang J, Dai J, Yao Z, et al. 2003. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63:7883-7890.
29. Camacho NP, Raggio CL, Doty SB, et al. 2001. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 69:94-101.
30. Flick LM, Weaver JM, Ulrich-Vinther M, et al. 2003. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res 21:676-684.
31. Chipman SD, Sweet HO, McBride DJ Jr, et al. 1993. Defective pro alpha 2(1) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci USA 90:1701-1705.
32. Manigrasso MB, O'Connor JP. 2004. Characterization of a closed femur fracture model in mice. J Orthop Trauma 18:687-695.
33. Yang KH, Park SJ. 2001. Stimulation of fracture healing in a canine ulna full-defect model by low-intensity pulsed ultrasound. Yonsei Med J 42:503-508.
34. Bonnarens F, Einhorn TA. 1984. Production of a standard closed fracture in laboratory animal bone. J Orthop Res 2:97-101.
35. Yang X, Bostrom MPG, Raggio C, et al. 2001. The effect of alendronate on fracture healing of wild type and osteogenesis imperfecta mice Transactions of the Forty-Seventh Annual Meeting of Orthopaedic Research Society
36. Winquist RA, Hansen ST Jr. 1980. Comminuted fractures of the femoral shaft treated by intramedullary nailing. Orthop Clin North Am 11:633-648.
37. Huang A, Raggio C, Fritton J, et al. 2005. Comparison of radiographic and micro-CT determined parameters in mouse bone specimens 51st Annual Meeting of the Orthopaedic Research Society.
38. McCarthy EA, Raggio CL, Hossack MD, et al. 2002. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 52:660-670.
39. Einhorn TA. 1998. The cell and molecular biology of fracture healing. Clin Orthop Relat Res (355 Suppl):S7-S21.
40. Kon T, Cho TJ, Aizawa T, et al. 2001. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 16:1004-1014.
41. Hyvonen PM, Karhi T, Kosma VM, et al. 1994. The influence of dichloromethylene bisphosphonate on the healing of a long bone fracture, composition of bone mineral and histology of bone in the rat. Pharmacol Toxicol 75:384-390.
42. Nyman MT, Gao T, Lindholm TC, et al. 1996. Healing of a tibial double osteotomy is modified by clodronate administration. Arch Orthop Trauma Surg 115:111-114.
43. Goodship AE, Walker PC, McNally D, et al. 1994. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5 (Suppl 7):S53-S55.
44. Peter CP, Cook WO, Nunamaker DM, et al. 1996. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14:74-79.
45. Madsen JE, Berg-Larsen T, Kirkeby OJ, et al. 1998. No adverse effects of clodronate on fracture healing in rats. Acta Orthop Scand 69:532-536.
46. Koivukangas A, Tuukkanen J, Kippo K, et al. 2003. Long-term administration of clodronate does not prevent fracture healing in rats. Clin Orthop Relat Res 408:268-278.
47. Cao Y, Mori S, Mashiba T, et al. 2002. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237-2246.
48. Li C, Mori S, Li J, et al. 2001. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16:429-436.
49. Li J, Mori S, Kaji Y, et al. 1999. Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 14:969-979.
50. Chao EY, Inoue N, Elias JJ, et al. 1998. Enhancement of fracture healing by mechanical and surgical intervention. Clin1 Orthop Relat Res (355 Suppl):S163-S178.
51. Lenehan TM, Balligand M, Nunamaker DM, et al. 1985. Effect of EHDP on fracture healing in dogs. J Orthop Res 3:499-507.
52. Nyman MT, Paavolainen P, Lindholm TS. 1993. Clodronate increases the calcium content in fracture callus. An experimental study in rats. Arch Orthop Trauma Surg 112:228-231.
53. Fleisch H. 2001. Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16:437-440.
54. Misof BM, Roschger P, Baldini T, et al. 2005. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 36:150-158.
55. Jepsen KJ, Pennington DE, Lee YL, et al. 2001. Bone brittleness varies with genetic background in A/J and C57BL/6J inbred mice. J Bone Miner Res 16:1854-1862.
56. Min H, Morony S, Sarosi I, et al. 2000. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474.
57. Frost HM. 1989. The biology of fracture healing. An overview for clinicians. Part II. Clin Orthop Relat Res 248:294-309.
58. Nakamura T, Hara Y, Tagawa M, et al. 1998. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J Bone Miner Res 13:942-949.
59. Smith BB, Cosenza ME, Mancini A, et al. 2003. A toxicity profile of osteoprotegerin in the cynomolgus monkey. Int J Toxicol 22:403-412.